Studying How Phosphate Treatment Affects Aging in Patients with XLH and HHRH

What this Trial Is About

Researchers are studying how long-term use and dosage of phosphate therapy affect kidney, blood vessel, and heart function in people with hereditary hypophosphatemic rickets with hypercalciuria HHRH and X-linked hypophosphatemia XLH. The study aims to compare cardiovascular and vascular health between these two groups, focusing on the impact of phosphate treatment over time and the immediate response to phosphate intake. This research involves collaboration between pediatric and adult endocrinology specialists using existing patient data. Participants include patients with HHRH and XLH who will receive phosphate supplements to reach a daily intake of 3,500 mg through dietary and supplemental sources. Some patients will take phosphate treatment for 30 days to study its effects. The study groups consist of patients with HHRH and XLH, including subgroups receiving active phosphate treatment. The study is non-randomized and open-label. Throughout the study, participants will provide medical history and undergo assessments including measurements of parathyroid hormone PTH and fibroblast growth factor 23 FGF23 levels after 30 days. Researchers will monitor kidney, cardiovascular, and vascular health using various tests and will track treatment adherence. The study began in 2019 and is expected to continue until 2028, with ongoing evaluations of phosphate therapys effects on aging-related health outcomes.

The Impact of Phosphate Metabolism on Healthy Aging